Cardiac (myo)fibroblast: Novel strategies for its targeting following myocardial infarction.

TitleCardiac (myo)fibroblast: Novel strategies for its targeting following myocardial infarction.
Publication TypeJournal Article
Year of Publication2014
AuthorsDaskalopoulos, E.P., Hermans K.C.M., Blankesteijn M.W.
JournalCurr Pharm Des
Volume20
Pagination1987-2002
Date Published2014
ISSN1873-4286
KeywordsAnimals, Cell Differentiation, Cytokines, Humans, Myocardial Infarction, Myofibroblasts, Signal Transduction, Transforming Growth Factor beta, Wound Healing
Abstract

Following myocardial infarction (MI), a dynamic and complex process called wound healing is initiated, aiming to produce a robust scar and limit adverse remodeling of the left ventricle (LV). Cardiac fibroblasts (CFs) - the most populous cardiac cell-type - differentiate into myofibroblasts under the influence of post-MI mechanical stress, transforming growth factor β (TGF-β) and various inflammatory signals. Myofibroblasts are contractile cells that start producing extracellular matrix (ECM) components and secrete factors that orchestrate wound healing, but also promote adverse cardiac remodeling that can progress to life-threatening heart failure (HF). Due to their vital role in the wound healing and LV remodeling after MI, (myo)fibroblasts have been receiving more and more attention lately as targets for anti-HF treatment strategies. In this review, we will summarize the current knowledge regarding the cardiac (myo)fibroblast characteristics, discuss the signaling pathways and the factors that affect their migration, proliferation and differentiation post-MI, as well as their ECM-depositing capabilities. Finally, we will provide an overview of the latest innovative research that is targeting the (myo)fibroblast, in an attempt to limit adverse remodeling and prevent HF.

Alternate JournalCurr. Pharm. Des.
PubMed ID23844732
19/03/2015